PACS Group is a $5.5B skilled nursing facility (SNF) operator. The stock is up 266% over 12 months. Three concurrent legal matters are pending: a DOJ Criminal Division HIPAA subpoena (received Feb 2025), an active SEC Division of Enforcement investigation (disclosed FY2025 10-K), and a securities fraud class action led by 1199SEIU pension fund. Material weaknesses in revenue recognition controls remain unremediated for a second year. An April 27, 2026 8-K shows the co-founder named as a fraud defendant exiting executive officer status mid-litigation.

What the filings say

FY2025 10-K (Feb 27, 2026): Revenue $5.289B (+29.4% YoY), Adjusted EBITDA $505M (+80.7%), net income $191.5M (3.5x). The growth driver is skilled mix — Medicare and managed care patient days as % of total — at 38% (2023) → 42% (2024) → 56% (2025).

DOJ Criminal Division HIPAA subpoena (received Feb 26, 2025): scope covers "practices and incentives pertaining to completion and submission of Minimum Data Set Assessments and the resulting PDPM rates." MDS assessments determine PDPM rates which determine Medicare reimbursement per skilled patient. The metric driving 80% EBITDA improvement is the metric under criminal investigation.

Material weaknesses in revenue recognition unremediated from 2024; new weaknesses identified in FY2025. Management states: "remediation actions have not yet been fully implemented."

Securities class action (Manchin v. PACS, SDNY): consolidated complaint Dec 19, 2025 alleges a "multi-year scheme" via three theories — COVID waiver patient flips, unnecessary Medicare Part B billing, falsified licensure/staffing — matching DOJ subpoena scope. Lead plaintiff 1199SEIU; counsel Labaton Keller Sucharow. MTD reply June 4, 2026; ruling expected Q3 2026.

April 27 8-K: Mark Hancock (named defendant) ceases Interim CFO; retires as executive officer June 30 — removing SOX 302/906 certification obligations — retains board seat as Vice Chairman. External CFO Carey Hendrickson (ex-USPH, ex-Capital Senior Living) appointed at $475K base + $3.8M target bonus + $2M RSU. No skilled-nursing or PDPM background.

What the market thinks

Forward P/E 16.45x. Sell-side: 6/6 bullish, $44 mean target. Short interest 9.4%, 5.8 days to cover (not crowded). ATM implied volatility 96.6%, backwardated to 66.4% by September. Calls bid 5.6% over puts.

The equity market and the options market disagree about whether this is a binary. ATM IV at 96.6% on a name with sell-side consensus implies the vol market is pricing material event risk that the analyst targets and current multiple do not reflect. We can't pin a clean implied probability without solving the full vol surface, but the disagreement is structural: equity holders are anchored to the EBITDA growth multiple, options dealers are pricing toward a Q3 binary.

Our scenario weights put bear-regime probability (MTD denial + meaningful equity drawdown) in the 50-65% range, with strong-bear tails (DOJ acceleration, restatement) at 15-20%. That is materially bearish relative to a $44 sell-side mean.

Why the gap exists

The causal chain — skilled mix improvement = the MDS/PDPM rate practices specifically named in the DOJ subpoena — requires connecting two different filings (10-K MD&A growth narrative with 10-K Legal Proceedings disclosure). Six analysts cover the name, all bullish, all anchored on the EBITDA print. No published sell-side note has framed the chain explicitly.

Secondary reasons: the Hindenburg short report is 18 months old and longs have already absorbed and bought the recovery; Q4 2025 beat (+25.7%) generates narrative momentum that overwrites legal overhang; material weaknesses get filed mentally as accounting nuisance rather than fraud tell. Insider Form 4 activity is internally consistent with the bear case — Hancock gifted $10.6M of stock March 5, Jergensen sold $1.25M same period, zero open-market P-code purchases by any officer — but Form 4 readers and momentum buyers are different audiences.

Risks (ranked)

1. May 7 Q1 earnings beat — low bar ($0.41 est, three prior misses); a beat extends narrative momentum and crushes vol.
2. MTD granted with leave to amend (estimated 10-15%) — squeeze potential, but DOJ/SEC vectors remain intact.
3. Industry-wide skilled mix improvement — if ENSG and other SNF operators show similar mix gains as a sector dynamic, the fraud-specificity weakens.
4. Successful MW remediation under Hendrickson — Q1 10-Q certification of completed remediation would invert the governance read (mechanically unlikely in 14-18 days, but possible).
5. DOJ declination or strategic acquirer bid (estimated 5-10%) — clean bull resolution to $50+.

Catalysts

• May 7, 2026: Q1 2026 earnings
• May 11-15: Q1 2026 10-Q (Hendrickson's first signed filing; Offer Letter exhibit)
• June 4: MTD reply due
• June 30: Hancock retires as executive officer
• Q3 2026 (Aug-Sep): MTD ruling — primary catalyst
• 12-24 months: DOJ Criminal / SEC Enforcement resolution

What would change our mind

• Any officer or director open-market P-code purchase after April 27 (currently zero; the gift + sell pattern is internally consistent with the bear thesis).
• DOJ public declination or closure of the criminal investigation.
• ENSG, SBRA, OHI, or another SNF peer discloses an analogous DOJ subpoena covering MDS/PDPM practices — converts company-specific fraud signal into industry-wide enforcement and shifts the analytical frame.
• MTD granted with prejudice (full dismissal, no leave to amend) — collapses the securities class action vector.
• Hendrickson certifies Q1 10-Q with material weaknesses declared fully remediated.

Evidence